Market news
InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moby summary of InspireMD, Inc.'s Q2 2026 earnings call
InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Inspiremd Inc (NSPR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Inspiremd Inc (NSPR-Q) from The Globe and Mail including charting and trades.
InspireMD (NSPR) said Thursday it received a deficiency notice from Nasdaq (NDAQ) because its stock
Detailed price information for Inspiremd Inc (NSPR-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.